Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis
CPT: Pharmacometrics & Systems Pharmacology · 2025-06 · 14 (6) · 1032-1041
DOI: 10.1002/psp4.70014 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 20.03.2025. Verfasst von Stefan P H van den Berg und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunopathology, Sanquin Research Amsterdam, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Natalizumab, Models, Biological, Multiple Sclerosis, Relapsing-Remitting, Immunologic Factors. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Intravenous natalizumab is an effective treatment for relapsing–remitting multiple sclerosis. However, the standard treatment interval of 4 weeks may be excessive for many patients. Personalized interval extension using therapeutic drug monitoring (TDM) can result in adequate drug exposure while reducing hospital visits and healthcare costs. Here, we investigate to which extent TDM‐guided personalized dosing can benefit from model‐informed precision dosing (MIPD). Individual posterior PK estimates were derived using patient weight and two trough concentrations at the standard dose interval by Bayesian estimation using a newly developed population PK model. MIPD was compared to a previously deployed TDM‐guided stratified personalized dosing protocol (SPD) using a decision tree to personalize dosing intervals. Accuracy (mean prediction error) of the predicted dosing intervals was 4.8% versus 24% for model‐informed estimates versus decision tree, respectively, when aiming for a 10 μg/mL trough concentration, and 4.8% versus 86% when aiming for 5 μg/mL. Corresponding precision (root mean square error) was 2.3 versus 4.0, and 1.5 versus 5 μg/mL. Finally, we evaluated the feasibility of a MIPD approach to attain a therapeutic trough of 2 μg/mL. Simulating MIPD showed a reduction in the average infusions versus the standard interval by 40%, with an average dose interval of 7 weeks, while maintaining adequate drug exposure. MIPD was concluded to be superior to the conventional TDM‐guided personalized dosing approach in terms of enhanced precision in individual dose interval selection, enabling more efficient interval extensions. Simulations supported the clinical deployment of natalizumab MIPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunopathology, Sanquin Research Amsterdam, Amsterdam, the Netherlands.
- Amsterdam UMC Location Vrije Universiteit Amsterdam, Molecular Cell Biology and Immunology, Amsterdam, the Netherlands.
- Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands.
- MS Center Amsterdam, Neurology, Vrije Universiteit Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands.
- Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Location Reade Amsterdam, Amsterdam, the Netherlands.
- Department of Pharmacy, Uppsala University, Uppsala, Sweden.
ORCID-Profile: Thomas P C Dorlo
Zitieren
APA
van den Berg, S. P. H., Toorop, A. A., Hooijberg, F., Wolbink, G., Voelkner, N. M. F., Gelissen, L. M. Y., Killestein, J., van Kempen, Z. L. E., Dorlo, T. P. C., & Rispens, T. (2025). Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis. CPT: Pharmacometrics & Systems Pharmacology, 14(6), 1032-1041. https://doi.org/10.1002/psp4.70014
Vancouver
van den Berg SPH, Toorop AA, Hooijberg F, Wolbink G, Voelkner NMF, Gelissen LMY, et al. Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis. CPT: Pharmacometrics & Systems Pharmacology. 2025;14(6):1032-1041. doi:10.1002/psp4.70014
BibTeX
@article{vandenBerg2025,
author = {van den Berg, Stefan P H and Toorop, Alyssa A and Hooijberg, Femke and Wolbink, Gertjan and Voelkner, Nivea M F and Gelissen, Liza M Y and Killestein, Joep and van Kempen, Zoé L E and Dorlo, Thomas P C and Rispens, Theo},
title = {Pharmacokinetic Model‐Informed Precision Dosing of Natalizumab in Multiple Sclerosis},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2025},
volume = {14},
number = {6},
pages = {1032--1041},
doi = {10.1002/psp4.70014}
}
EUVIMED